SNU-5 In Vitro MTT Assay (Cell Viability)

This assay is to provide SNU-5-based In Vitro MTT Assay (Cell Viability) to accelerate our client's oncology projects. The assay will be customized according to the specific requirements. Please contact our scientists to discuss more details.

SNU-5

Human

SNU-5 was line derived in 1987 by J. Park and associates from ascites of a patient with poorly differentiated carcinoma of the stomach. The patient had previously received chemotherapy including 5-fluorouracil, doxorubicin and mitomycin-C.
Derived from metastatic site, ascites

Gastric Carcinoma

Oncology

In Vitro MTT Assay (Cell Viability)

SNU-5-cell based In Vitro MTT Assay (Cell Viability)

The MTT (3-(4,5-dimeth ylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay is one of most commonly used assays for cancer drug screening. This assay has been very popular among cancer researchers as an initial assay in drug discovery. NAD(P)H-dependent oxidoreductase or dehydrogenases in viable cells can reduce MTT into purple-colored formazan, which can then be solubilized for spectrophotometric analysis.

MTT (3-(4,5-dimeth ylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) Assay

Cell Viability/Cytotoxicity and Antiproliferative Assays

Uncontrolled proliferation is one of the main features of cancer cells. Cell-based in vitro assays are employed to determine whether test molecules possess direct cytotoxic/antiproliferative effects in cancer cells.

Cell Viability Assay

Cell-based Viability Assays Based on Cellular Enzymes and Proteins